Updates are available Correction dated 2021-08-04
Click to view Correction: https://doi.org/10.1007/s11102-021-01177-w
-
Authors
Labadzhyan, Artak
Nachtigall, L B
Fleseriu, M http://orcid.org/0000-0001-9284-6289
Gordon, M B
Molitch, M
Kennedy, L
Samson, S L http://orcid.org/0000-0002-8159-7093
Greenman, Y http://orcid.org/0000-0003-4923-488X
Biermasz, N http://orcid.org/0000-0001-5817-3594
Bolanowski, M http://orcid.org/0000-0002-2360-6596
Haviv, A
Ludlam, W
Patou, G
Strasburger, C J http://orcid.org/0000-0001-7905-7357
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03252353 at ClinicalTrials.govnct01412424 at ClinicalTrials.govDocuments that mention this clinical trial
Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results
https://doi.org/10.1007/s11102-021-01163-2
Documents that mention this clinical trial
Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results
https://doi.org/10.1007/s11102-021-01163-2
-
Funding
Funding for this research was provided by:
Chiasma Inc. (Chiasma Inc.)
- License Information
-
More Information
Article History
Accepted: 11 June 2021
First Online: 25 June 2021
Change Date: 4 August 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s11102-021-01177-w
Declarations
:
: AL reports no conflicts of interest. LBN served as research support for Chiasma and received grant support from and served as a consultant for Ipsen. MF received a research grant to Oregon Health and Science University as principal investigator for Crinetics, Chiasma, Ionis, Novartis, Recordati and served as a scientific consultant for Crinetics, Chiasma, Ionis, Ipsen, Novartis, Pfizer, and Recordati. MBG received research support from Chiasma, Corcept, Crinetics, Ipsen, Novartis, Opico, Pfizer, Strongbridge, Teva, and Novo Nordisk and served as a scientific consultant for Chiasma and Novo Nordisk. MM received research grant to institution from Chiasma, Novartis, and Crinetics and received a consultation honorarium from Chiasma. LK served as a clinical trial principal investigator for Chiasma and Ionis and served as a consultant for Pfizer. SLS served as site principal investigator, steering chair, and consultant for Chiasma and Novartis. YG received funding in the form of a research grant from Pfizer and was compensated for serving as principal investigator of research grants to Tel Aviv-Sourasky Medical Center from Chiasma and Strongbridge Biopharma, and also received consultation fees from Tiburio and lecture fees from CTS. NB reports no conflicts of interest. MB received a research grant from Ispen and lecture fees from Ispen, Novartis, Pfizer, and Recordati, and also served as an advisory board member for Novartis, Pfizer, and Recordati. AH, WHL, GP are employees of Chiasma. CJS received consultancy fees and speaker honoraria from Chiasma, Pfizer, Ipsen, and Crinetics.
: This trial was performed in accordance with the principles stated in the Declaration of Helsinki. Prior to starting the trials, ethical approval was obtained for all protocols from the local Institutional Review Board or other appropriate ethics committee to confirm the trials meet national and international guidelines for research on humans.
: Informed consent was obtained from all individual participants included in the trials.
